S. Truong

Most-cited papers

1. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

   T. Zenz, D. Vollmer, M. Trbušek, J. Šmardová +24 more

   2010Leukemia183 citations

   Semantic Scholar

   Save

2. TP53 Mutational signature for aristolochic acid: an environmental carcinogen

   M. Moriya, N. Slade, B. Brdar, Z. Medverec +6 more

   2011International Journal of Cancer114 citations

   Semantic Scholar

   Save

3. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.

   A. Dufour, G. Palermo, E. Zellmeier, Gudrun Mellert +23 more

   2013Blood38 citations

   Semantic Scholar

   Save

4. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling

   S. Chiaretti, Simona Tavolaro, M. Marinelli, M. Messina +14 more

   2011Genes, Chromosomes and Cancer33 citations

   Semantic Scholar

   Save

5. TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

   T. Zenz, P. Hoth, R. Busch, H. Helfrich +16 more

   200923 citations

   Semantic Scholar

   Save

6. Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.

   Pedro Farinha, L. Sehn, B. Skinnider, Lin Wu +4 more

   200616 citations

   Semantic Scholar

   Save

7. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods

   B. Kantorová, J. Malčíková, J. Šmardová, Š. Pavlová +13 more

   2015Tumor Biology12 citations

   Semantic Scholar

   Save

8. TP53 abnormalities in chronic lymphocytic leukemia exhibit a disease specific profile: meta-analysis of 270 mutations.

   T. Zenz, J. Šmardová, D. Vollmer, M. Trbušek +16 more

   20085 citations

   Semantic Scholar

   Save

9. Inactivation of TP 53 correlates with disease progression and low miR-34 a expression in previously treated chronic lymphocytic leukemia patients

   A. Dufour, G. Palermo, E. Zellmeier, Gudrun Mellert +23 more

   20133 citations

   Semantic Scholar

   Save

10. Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.

    K. Young, N. Patten, S. Truong, J. Eickhoff +34 more

    20091 citations

    Semantic Scholar

    Save

11. The clinical relevance of p53 isoforms modifying the effects of p53 mutation on survival from breast cancer

    A. Thompson, N. Patten, A. Diot, S. Truong +6 more

    20071 citations

    Semantic Scholar

    Save

12. High Frequency of P53 Mutations Detected by a Microarray Resequencing Assay, the AmpliChip P53 Test, in AML with a Complex Aberrant Karyotype.

    N. Patten, S. Truong, Jeff Fu, F. Dicker +6 more

    20061 citations

    Semantic Scholar

    Save

13. Mutational Analysis of TP53 Gene in Chronic Lymphocytic Leukemia: Comparison of Different Methodological Approaches

    B. Kantorová, J. Malčíková, Jana Kmínková, V. Navrkalova +14 more

    20120 citations

    Semantic Scholar

    Save

14. Evaluation of TP53 mutations in chronic lymphocytic leukemiausing resequencing microarray platforms

    J. Lochmanová, J. Malčíková, J. Šmardová, Lin Wu +13 more

    20110 citations

    Semantic Scholar

    Save

15. Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

    A. Dufour, S. Bohlander, E. Zellmeier, Gudrun Mellert +22 more

    20110 citations

    Semantic Scholar

    Save

16. Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

    A. Dufour, S. Bohlander, E. Zellmeier, Gudrun Mellert +22 more

    20110 citations

    Semantic Scholar

    Save

17. EVALUATION OF TP53 MUTATIONS WITH THE AMPLICHIP P53 ARRAY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): HIGHER SENSITIVITY AND CORRELATION WITH CLINICAL OUTCOME

    I. Del Giudice, S. Chiaretti, A. Guarini, R. Foa +14 more

    20100 citations

    Semantic Scholar

    Save

18. 17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution

    T. Zenz, A. Sarno, S. Häbe, T. Denzel +11 more

    20080 citations

    Semantic Scholar

    Save

19. P53 EVALUATION IN CLL BY P53 ARRAY: A SIMPLE, SENSITIVE AND SPECIFIC METHOD THAT UNRAVELS A HIGH PERCENTAGE OF POLYMORPHISMS AND MUTATIONS

    I. Del Giudice, S. Chiaretti, A. Guarini, R. Foa +9 more

    20080 citations

    Semantic Scholar

    Save

20. P53 EVALUATION IN 98 CLL PATIENTS BY AMPLICHIP P53 ARRAY REVEALS A HIGH PERCENTAGE OF MUTATIONS AND POLYMORPHISMS

    I. Del Giudice, S. Chiaretti, A. Guarini, R. Foa +9 more

    20080 citations

    Semantic Scholar

    Save

21. Role of p53 mutations in clinical and pathological responses in an open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2-) breast cancer (BC)

    S. Truong, N. Patten, D. Tripathy, S. Glück +2 more

    20070 citations

    Semantic Scholar

    Save

22. 2060 POSTER An open-label study of neoadjuvant capecitabine (C) and docetaxel (D) with/without trastuzumab (T) to determine the role of p53 mutations in clinical and pathological responses in patients with recently diagnosed breast cancer (BC)

    P. Nancy, S. Truong, D. Tripathy, S. Glück +2 more

    20070 citations

    Semantic Scholar

    Save